Teva’s Austedo XR (deutetrabenazine) Extended-Release Tablets Receives the US FDA’s Approval for Tardive Dyskinesia and Chorea Associated with Huntington’s Disease
Shots:
- The US FDA has approved Austedo XR (vesicular monoamine transporter 2 inhibitors), a new qd formulation of deutetrabenazine for adults with tardive dyskinesia (TD) and chorea associated with Huntington’s disease. The product is expected to be available in the US in 2023
- When switching b/w Austedo (BID) tablets and Austedo XR (qd) tablets, the qd formulation of Austedo XR was therapeutically equivalent to the BID formulation.
- Austedo XR is supplied as 6mg, 12mg, and 24mg strength extended-release tablets and can be taken with/without food. Additionally, the product was approved in the US for adults for the same indication
Ref: Teva | Image: Teva
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
